Skip to content
Lower risk Drug recall · FDA · Published June 13, 2019

B. Braun Medical Heparin Sodium Recall: Subpotent Drug Risk

B. Braun Medical recalls heparin sodium 25,000 USP units per 250mL in 5% dextrose injection due to subpotent drug levels. This may cause ineffective blood thinning during medical procedures.

🇺🇸 FDA recall #D-1343-2019DrugB. Braun Medical ›
Take action

Contact the company

Recalling firmB. Braun Medical Inc2525 Mcgaw Ave · Irvine, CA 92614-5841
✎ GovInfoNow plain-language explainer

B. Braun Medical is recalling heparin sodium injections that may have lower-than-stated blood-thinning potency. Using these products could lead to ineffective blood clot prevention during medical procedures. Read more at govinfonow.com/recall/38640-b-braun-medical-heparin-sodium-recall-subpotent-drug-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/38640-b-braun-medical-heparin-sodium-recall-subpotent-drug-risk · Updated October 5, 2026 · FDA enforcement record: FDA #D-1343-2019

Cite this page

“B. Braun Medical Heparin Sodium Recall: Subpotent Drug Risk.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/38640-b-braun-medical-heparin-sodium-recall-subpotent-drug-risk. Based on FDA recall #D-1343-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1343-2019%22&limit=1).

The FDA announced on June 13, 2019, that B. Braun Medical Inc. voluntarily recalled Heparin Sodium 25,000 USP units per 250 mL in 5% Dextrose Injection due to subpotent drug risks. The agency stated the recall was initiated by the firm.

How to tell if you have it

  • Brand: B. Braun Medical
  • Product: Heparin Sodium 25,000 USP units per 250 mL (100 USP units per mL) in 5% Dextrose Injection, 250 mL EXCEL Container bag
  • NDC: 0264-9587-20
  • Lot #: J7B259
  • Expiration: 31 Aug 2019
  • Quantity: 40,176 bags

The hazard

The recall addresses low out-of-specification results for the drug anti-factor IIa potency. This defect means the heparin potency may not meet USP specifications.

Context

GovInfoNow's records show B Braun Medical Inc has 66 other recalls on record since October 15, 2013. Other recent recalls of similar products include Somerset Therapeutics Cisatracurium Besylate Injection Recall (November 26, 2025), OneSource Specialty Pharma Methohexital Sodium Recall (June 7, 2026), and Par Health Buprenorphine Injection Recall (June 12, 2026).

How to tell if you have this one

Check for the product name 'Heparin Sodium 25,000 USP units per 250 mL (100 USP units per mL) in 5% Dextrose Injection, 250 mL EXCEL Container bag'. The lot number J7B259 with expiration date August 31, 2019 is affected.

  • Brand
    B. Braun Medical
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Verify the lot number and expiration date on the product label to confirm if it's affected.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 3.1 years after the firm started it.

1. Firm started the recall: Jun 13, 201912. FDA classified it Class II: Jun 13, 201923. Published in FDA’s Enforcement Report: Jun 19, 201934. FDA terminated the recall: Jul 15, 2022420192022
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

✎ GovInfoNow

Questions people ask

Is this product safe to use?

The recall indicates potential subpotency, meaning it may not work as intended. Do not use if you have the affected lot number.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1343-2019 (June 13, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1343-2019 to see it in context.
  • Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA